Arsenic Trioxide During Consolidation for Patients with Previously Untreated Low/Intermediate Risk Acute Promyelocytic Leukaemia May Eliminate the Need for Maintenance Therapy

A total of 105 patients (age ≥ 18 years) with newly diagnosed low or intermediate risk acute promyelocytic leukaemia (APL) were treated with a standard induction and consolidation regimen including arsenic trioxide (ATO). Sixty-eight patients who were polymerase chain reaction (PCR) negative for PML...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Coutre, Steven E., Othus, Megan, Powell, Bayard, Willman, Cheryl L., Stock, Wendy, Paietta, Elisabeth, Levitan, Denise, Wetzler, Meir, Attar, Eyal C., Altman, Jessica K., Gore, Steven D., Maher, Tracy, Kopecky, Kenneth J., Tallman, Martin S., Larson, Richard A., Appelbaum, Frederick R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4064464/
https://ncbi.nlm.nih.gov/pubmed/24528179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12775
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi